- Coordinator
- Bioprotect Ltd, Israel
- Runs
- 1 October 2023 to 30 September 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €5.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190160766
What the project is doing
In the project's own words, from its summary on CORDIS.
Prostate is the 2nd leading cancer in men in the world, with more than 1.4 million men diagnosed every year globally. ~50% of men will be treated with radiation treatment. Radiation is a highly effective treatment; however, it has significant complications, mainly injuring the rectal tissue, approximate to the prostate treatment area. Up to 35% of the patients will experience rectal toxicity side effects such as bleeding, urinary, bowl and erectile dysfunction, damaging severely patient’s quality of life.
There is a growing need for a solution that protects the rectum from the radiation field. Our soluton ‘ProSpace’ is a biodegradable medical grade copolymer (70:30 Poly L-Lactide-co-ε-Caprolactone) balloon spacer deployed in the prostate-rectum interspace. It creates a 1.8cm, symmetric distance between the prostate & rectum, allowing physicians to radiate prostate tumours & sparing healthy rectal tissue.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Bioprotect Ltd | Tzur Yigal | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI